Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xigris Impact on Vasoreactivity in Septic Shock
NCT02885168Phase 4Completed
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Feb 2008
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, open-label trial of drotrecogin alfa in septic shock, sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Vascular reactivity measured with dose-response to phenylephrine at 24 hours. Started Feb 2008; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02885168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885168.